Revelation Biosciences reports Q3 net loss of $2.2M; cash $6.5M into 2025

REVELATION BIOSCIENCES, INC.

2024-Q3 EPS reported -$7.38

Net loss Q3 2024: $2.2M ($0.84 per share) vs $2.6M loss in Q3 2023; nine-month net loss $13.3M vs net income $2.1M in prior year.
Cash and cash equivalents $6.5M as of Sep 30, 2024, down from $12.0M at Dec 31, 2023; raised $3.8M from warrant exercise in Aug 2024.
Clinical-stage biotech advancing Gemini; expects FDA IND acceptance to start Phase 1b in CKD patients; cash runway into 2025.
Net cash used in operations nine months: $14.6M vs $5.3M in 2023; cash burn increased significantly.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.